US-based Candid Therapeutics has signed another T-cell engager (TCE ... Candid will have exclusive global rights to a tri-specific TCE discovered by WuXi using its WuXiBody platform.

1Masonic Cancer Center, Minneapolis, Minnesota. 6Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota. 7Department of ...

Under the deal, Candid will have exclusive global rights to a tri-specific ... has “three T cell engager programmes targeting BCMA, CD20, and CD19 in or near clinical development”. Song added: “We are ...

Summarized in the table below are the results of all studies of bi-specific T cell engagers in prostate cancer: What about tri-specific T-cell engagers ... In 2023, a phase II trial of pembrolizumab + ...

The asset in question is a trispecific T-cell engager developed by WuXi’s multispecific antibody platform WuXiBody. Candid is eyeing getting the candidate into the clinic in the first half of 2026.

It is a tri-specific antibody and T cell engager. It is developed based on tri-specific T-cell activating construct (TriTAC) technology. It is administered through intravenous route. It was also under ...

(“Candid”), a clinical-stage biotechnology company focused on becoming the leader in advancing T ... T-cell Engager discovered at WuXi Biologics’ proprietary universal multispecific antibody ...

Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics' proprietary universal multispecific antibody ...

giving Candid exclusive global rights to a preclinical trispecific T-cell engager discovered on WuXi Biologics’ proprietary universal multispecific antibody platform WuXiBody™. WuXi Biologics ...